“Immunotherapy Biomarkers in the Gynecologic Tract: MMR, PD-L1, and Beyond”

Anne M. Mills, MD
Associate Professor of Pathology
Anatomic & Clinical Pathology Residency Program Director
Gynecologic & Breast Pathology Fellowship Director
University of Virginia Department of Pathology

At the conclusion of this activity, the participant will be able to:

1. Explain the role of mismatch repair, microsatellite instability testing, and tumor mutational burden in identifying candidates for checkpoint inhibition.
2. Confidently interpret PD-L1 immunostaining as a biomarker for anti-PD-1 checkpoint inhibition in cervical carcinoma.
3. Understand potential biomarkers in the pipeline such as POLE mutation testing, neoantigen load, and immunohistochemistry for MHC class I, checkpoint molecules (such as TIM-3, LAG-3, and VISTA), and immune-inhibitory enzymes (such as IDO1).